Altogether, these findings demonstrate the potential impacts of Cx30, Cx36, and Cx43 on PD and in the foreseeable future, it might be useful to focus on these gap-junction regulations in addition to chemical therapies for improving neurocognitive impairments in PD patients. This evidence concerns the gene GJB6 and Parkinson disease.